An interventional study of Blood Products transfusion in Liver Cirrhosis With Acute Decompensation, sponsored by Grigore T. Popa University of Medicine and Pharmacy. Recruiting at 1 site in Romania. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-27.
Sponsored by Grigore T. Popa University of Medicine and Pharmacy · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Liver Cirrhosis with a site in Romania — 6 open to participants now, 6 under way, 1 of them phase 3. Liver Cirrhosis · Romania.
Among the 22 studies in Liver Cirrhosis with a site in Romania, this one is the 11th largest by planned enrollment of the 16 interventional ones that give a count, is the only one that started in 2025, is one of 2 with no phase, and was the 21st registered.
1,303 studies on the registry are indexed under Liver Cirrhosis; 341 are open to participants now.
Browse Liver Cirrhosis studies →6 of the 22 studies in Liver Cirrhosis with a site in Romania are open now. Recruiting first, the newest first:
University Medical Center Groningen · Sites in Romania, Austria, Belgium and 9 more countries
Ages 18+
Boehringer Ingelheim · Sites in Romania, United States, Argentina and 34 more countries
Ages 18+
Carol Davila University of Medicine and Pharmacy · Sites in Romania
Ages 18+
Julius Clinical · Sites in Romania, Belgium, Czechia and 7 more countries
Ages 18–75
SUUMC Central Military Hospital Dr Carol Davila · Sites in Romania
Ages 18–75
A study can be open while its sites in Romania have not opened yet or have stopped. Only those recruiting at a site in Romania →
Of the 208 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 66 (32%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 116 is above the median of 78 across 742 interventional studies indexed under Liver Cirrhosis.
Median enrollment 223 across the 16 interventional studies, 1,417 across the 6 observational. Of the 15 that completed or were terminated, 6 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 22 have an industry lead sponsor. The 10 most frequent:
Grigore T. Popa University of Medicine and Pharmacy is the lead sponsor of 32 studies on the registry; 9 are open to participants now.
Grigore T. Popa University of Medicine and Pharmacy has 1 study filed under Liver Cirrhosis — fewer than ten, so there is no comparison to draw.
1 of the studies in Liver Cirrhosis with a site in Romania that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07585890University Medical Center GroningenEstablishing a Reference Framework for Outcomes After Machine-Preserved Liver Transplantation in Europe | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 22 studies in Liver Cirrhosis with a site in Romania, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Patients with liver cirrhosis have historically received prophylactic transfusions before invasive procedures with high risk of bleeding. The optimal method for establishing the need of blood transfusion before invasive procedures in cirrhotic patients has not been determined yet, and there are not enough scientific data to warrant empirical transfusion. In many surgical and trauma-related contexts, viscoelastic tests, like Rotational Thromboelastometry (ROTEM), offer a comprehensive assessment of hemostasis, and it has been demonstrated to predict bleeding risk more accurately than traditional coagulation tests. The aim of this project is to evaluate the efficacy of a ROTEM-based algorithm in managing the administration of prophylactic blood components to patients diagnosed with decompensated liver cirrhosis undergoing invasive high risk of bleeding procedures. The investigators hypothesized that ROTEM-based decision-making will lead to a reduction in pre-procedural blood component usage, particularly fresh frozen plasma (FFP), compared with standard of care, whilst maintaining optimal clinical outcomes. The investigators will perform a prospective, single-center, randomized controlled clinical trial in a tertiary university hospital in Romania, comparing ROTEM-guided prophylactic blood component administration to standard of care in patients with decompensated cirrhosis and coagulopathy undergoing invasive procedures. Inclusion criteria: adults (aged 18 years or older) admitted with cirrhosis and an indication for high risk of bleeding invasive procedure defined as: transjugular liver biopsy, transjugular intrahepatic portosystemic shunt, endoscopic retrograde cholangio-pancreatography with sphincterotomy, endoscopic polypectomy of polyps more than 1 cm, variceal banding and complex dental extraction. The primary safety endpoint will be the incidence of major bleeding. Secondary endpoints will be the proportion of blood products transfusion, hospital length of stay, in-hospital and 28-day mortality, incidence of minor bleeding, transfusion related adverse reactions, and cost analysis.
This project will compare two blood transfusion protocols (coagulogram-based and thromboelastometry-based) prior to high risk of bleeding procedures in patients with cirrhosis. The investigators hypothesized that thromboelastometry-guided transfusion protocols are safe and would decrease the need of blood products transfusion compared to an ordinary coagulogram-based protocol in patients with decompensated cirrhosis receiving high risk of bleeding procedures.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Takes into account the SCTs -PT/INR, platelet count and serum fibrinogen levels to guide transfusion prior to high risk of bleeding invasive procedure. If INR ≤1.8, platelet count ≥50,000/mm3 and serum fibrinogen ≥120 mg/dL, no transfusion is indicated. Otherwise, if INR \>1.8, FFP is transfused at 10 mL per kg of body weight; and/or if platelet count \<50,000/mm3, 1 unit per 10 kg of body weight of platelets (up to 10 units) is transfused; and/or if serum fibrinogen \<120 mg/dL, 1 unit per 10 kg of body weight of cryoprecipitate is transfused (up to 10 units).
Procedure: Blood Products transfusion
The thromboelastometry-based transfusion protocol uses EXTEM and FIBTEM. No transfusion is necessary when CT-EXTEM is ≤80 s and A10-EXTEM is ≥40 mm. For patients in whom CT-EXTEM is \>80 s, transfusion of 10 mL per kg of body weight of FFP will be performed. If the patient presents an A10-EXTEM \<40 mm, the investigators will further evaluate the A10-FIBTEM. If A10-FIBTEM is ≥10 mm (indicating adequate fibrinogen function), platelet units (1 unit per 10 kg of body weight; maximum 10 units) will be transfused. Otherwise, if A10-FIBTEM is \<10 mm (indicating fibrinogen deficiency), cryoprecipitate (1 unit per 10 kg of body weight; maximum 10 units) will be transfused.
Procedure: Blood Products transfusion
Blood Products transfusion
The proportion of patients transfused with any blood product
This measure represents the percentage of patients within the study population who received at least one transfusion of any blood component during study period. It is calculated by dividing the number of patients who were administered one or more units of a blood product by the total number of eligible patients in the cohort, and multiplying by 100 to express the result as a percentage. Blood products include platelets, fresh frozen plasma, or cryoprecipitate.
Time frame: From the enrollment to 30 days after the procedure
The incidence of major bleeding within the first 24 h
The incidence of major bleeding within the first 24 h after high risk of bleeding invasive procedures. It quantifies early clinically significant hemorrhagic complications and is typically expressed as a percentage or rate. For the purposes of this measure, major bleeding is defined according to standardized clinical criteria. Commonly applied definitions include adapted criteria from the International Society on Thrombosis and Haemostasis (ISTH) or similar consensus frameworks. A bleeding event is classified as major if it meets one or more of the following conditions: fatal bleeding, symptomatic bleeding in a critical area or organ (intracranial, intraspinal, intraocular, retroperitoneal, pericardial, or intramuscular with compartment syndrome), a decrease in hemoglobin of ≥2 g/dL (≥20 g/L) within 24 hours attributable to bleeding , transfusion of ≥2 units of packed red blood cells due to acute blood loss, bleeding requiring urgent procedural or surgical intervention.
Time frame: From the enrollment to 30 days after the procedure
The incidence of acute transfusion-related adverse events
This measure represents the proportion of transfusion episodes that are complicated by an acute transfusion-related adverse event occurring during or within 24 hours after the administration of a blood component. It will be expressed as a percentage and it will be calculated by dividing the number of transfusion episodes complicated by at least one qualifying acute adverse event by the total number of transfusion episodes administered during the study period. An acute transfusion-related adverse event is defined as a new clinical sign or symptom occurring during transfusion or within 24 hours after completion, for which a causal relationship to the transfused blood component is suspected, probable, or definite. The investigators will evaluate transfusion-associated cardiac overload, acute hemolytic transfusion reactions, anaphylactic reactions, febrile non-hemolytic reactions and urticarial reactions.
Time frame: From enrollment to 30 days after the procedure
The hospital length of stay
The investigators will evaluate the hospital length of stay in both study arms
Time frame: From enrollment to 30 days after the procedure
In hospital mortality
This measure represents the proportion of patients who die from any cause during hospital admission. It captures all-cause mortality occurring between the time of hospital admission and discharge and is typically expressed as a percentage of the total eligible patient population.
Time frame: From the enrollment to discharge or death
30-days mortality
This measure represents the proportion of patients who die from any cause within 30 days of a defined index event. The index event will be high risk of bleeding invasive procedure. The outcome will be expressed as a percentage and will reflect short-term mortality risk beyond the inpatient setting. 30-day mortality is defined as death from any cause occurring within 30 calendar days of the high risk of bleeding invasive procedure regardless of whether the patient is hospitalized, discharged, or transferred at the time of death. Mortality status will be evaluated through telephone follow-up with patients or family members
Time frame: From date of randomization until the end of the study or the date of death from any cause, whichever came first, assessed up to 30 days.
Plan to share: Undecided
Started Jun 2025 (actual). Primary completion is estimated for Jun 2026, 12 months after the start.
Of 207 non-industry interventional studies with no phase under Liver Cirrhosis, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 73. This study's planned 12 months is below that.
Counting every sponsor, half of 216 studies reached it within 32 months; a quarter within 17 and three quarters within 54.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Grigore T. Popa University of Medicine and Pharmacy